CD70 and neoplasm: Given that tissue-level expression data of prognostic biomarkers are particularly valuable in this aggressive cancer, our research gives a solid basis for validation and experimental studies in the future to underpin the role of the CD70/CD27 axis in SCLC tumor immunology.